Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

18 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Improvement of gastrointestinal health status in subjects consuming Lactobacillus reuteri NCIMB 30242 capsules: a post-hoc analysis of a randomized controlled trial.
Jones ML, Martoni CJ, Ganopolsky JG, Sulemankhil I, Ghali P, Prakash S. Jones ML, et al. Expert Opin Biol Ther. 2013 Dec;13(12):1643-51. doi: 10.1517/14712598.2013.833601. Epub 2013 Sep 28. Expert Opin Biol Ther. 2013. PMID: 24074303 Clinical Trial.
Oral supplementation with probiotic L. reuteri NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: a post hoc analysis of a randomized controlled trial.
Jones ML, Martoni CJ, Prakash S. Jones ML, et al. J Clin Endocrinol Metab. 2013 Jul;98(7):2944-51. doi: 10.1210/jc.2012-4262. Epub 2013 Apr 22. J Clin Endocrinol Metab. 2013. PMID: 23609838 Clinical Trial.
Cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications.
Jones ML, Tomaro-Duchesneau C, Martoni CJ, Prakash S. Jones ML, et al. Expert Opin Biol Ther. 2013 May;13(5):631-42. doi: 10.1517/14712598.2013.758706. Epub 2013 Jan 28. Expert Opin Biol Ther. 2013. PMID: 23350815 Review.
Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial.
Jones ML, Martoni CJ, Di Pietro E, Simon RR, Prakash S. Jones ML, et al. Regul Toxicol Pharmacol. 2012 Jul;63(2):313-20. doi: 10.1016/j.yrtph.2012.04.003. Epub 2012 Apr 25. Regul Toxicol Pharmacol. 2012. PMID: 22561556 Clinical Trial.
Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults.
Jones ML, Martoni CJ, Parent M, Prakash S. Jones ML, et al. Br J Nutr. 2012 May;107(10):1505-13. doi: 10.1017/S0007114511004703. Epub 2011 Nov 9. Br J Nutr. 2012. PMID: 22067612 Clinical Trial.
Evaluation of safety and tolerance of microencapsulated Lactobacillus reuteri NCIMB 30242 in a yogurt formulation: a randomized, placebo-controlled, double-blind study.
Jones ML, Martoni CJ, Tamber S, Parent M, Prakash S. Jones ML, et al. Food Chem Toxicol. 2012 Jun;50(6):2216-23. doi: 10.1016/j.fct.2012.03.010. Epub 2012 Mar 15. Food Chem Toxicol. 2012. PMID: 22425689 Clinical Trial.
Changes in bile acids, FGF-19 and sterol absorption in response to bile salt hydrolase active L. reuteri NCIMB 30242.
Martoni CJ, Labbé A, Ganopolsky JG, Prakash S, Jones ML. Martoni CJ, et al. Gut Microbes. 2015;6(1):57-65. doi: 10.1080/19490976.2015.1005474. Gut Microbes. 2015. PMID: 25612224 Free PMC article. Clinical Trial.
The human microbiome and bile acid metabolism: dysbiosis, dysmetabolism, disease and intervention.
Jones ML, Martoni CJ, Ganopolsky JG, Labbé A, Prakash S. Jones ML, et al. Among authors: martoni cj. Expert Opin Biol Ther. 2014 Apr;14(4):467-82. doi: 10.1517/14712598.2014.880420. Epub 2014 Jan 30. Expert Opin Biol Ther. 2014. PMID: 24479734 Review.
Diet-induced metabolic hamster model of nonalcoholic fatty liver disease.
Bhathena J, Kulamarva A, Martoni C, Urbanska AM, Malhotra M, Paul A, Prakash S. Bhathena J, et al. Diabetes Metab Syndr Obes. 2011;4:195-203. doi: 10.2147/DMSO.S18435. Epub 2011 Jun 3. Diabetes Metab Syndr Obes. 2011. PMID: 21760736 Free PMC article.
18 results
Jump to page
Feedback